Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK111 in Moderate to Severe Plaque Psoriasis
NCT06066125Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gumokimab in plaque psoriasis (3 arms), sponsored by Akeso, Inc. Primary endpoints: Percentage of subjects achieving at least 75% reduction in Psoriasis Area and Severity Index at 12 weeks and Percentage of subjects achieving static Physician Global Assessment 0 or 1 at 12 weeks. Started Mar 2023; status: completed.
02
Drugs
gumokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06066125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066125.